- In April 2025, Thermo Fisher Scientific launched a new automated equilibrium dialysis system tailored for biologics research. It integrates robotic liquid handling and LIMS connectivity to ensure compliant data capture and significantly higher throughput—accelerating pharmacokinetic workflows
- In February 2024, Stratagem Market Insights released an in-depth report projecting IRD market trends through 2030, including segmental forecasts, competitive analysis of key players (such as Harvard Apparatus, Thermo Fisher, Merck, and BioDuro), and regional dynamics
- In May 2025, Opus Genetics presented emerging data on its IRD gene therapy programs at several medical conferences. The company showcased ongoing clinical progress and novel pipeline candidates, signaling growing momentum in gene-based IRD treatments
- In May 2025, researchers at the University of Pennsylvania unveiled advanced tools and platforms aimed at treating late-stage IRDs—highlighting more versatile gene therapy and regenerative strategies for severe conditions such as retinitis pigmentosa
- In May 2025, Beacon Therapeutics shared interim 6-month data from its Phase 2 trial of laru-zova for X-linked retinitis pigmentosa (XLRP). The results provide early insights into therapeutic efficacy and safety in this underserved patient subgroup
